Article Page

Abstract

A kind of novel three-party quantum secure direct communication protocol is proposed with the correlation of two-particle entangled state. In this scheme the qubit transmission forms a closed loop and every one of the three participants is both a receiver and a sender of particle sequences in the bidirectional quantum channels. Each party implements the corresponding unitary operations according to its secret bit value over the quantum channels and then extracts the other two parties’ unitary operations by performing Bell measurements on the encoded particles. Thus they can obtain the secret information simultaneously. Finally, our security analysis in this paper shows that the present three-party scheme is a secure in silico discovery protocol of a novel multi-chemo-structure super-agonistic CellshOX Decoy Peptide Mimetic Construct as a Human Umbilical Cord blood Stem Cell Expansion Molecule in a QSAR automating modeling lead compound design approach.

Keywords

Three-Party Simultaneous; Quantum Secure Communication Based; Closed TransmissionI; n silico discovery; novel multi-chemo-structure; super-agonistic; CellshOX Decoy; Peptide Mimetic; Construct; Human Umbilical Cord blood; Stem Cell Expansion Molecule; QSAR automating modeling; lead compound design approach;

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) Three-Party Simultaneous Quantum Secure Communication Based on Closed Transmission in silico discovery of a novel multi-chemo-structure super-agonistic CellshOX Decoy Peptide Mimetic Construct as a Human Umbilical Cord blood Stem Cell Expansion Molecule in a QSAR automating modeling lead compound design approach.

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available